MetLife Investment Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

MetLife Investment Management’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-24,907	Closed	-$595K	–	2525
2021 Q1	$595K	Sell	24,907 -5,849	-19%	-$109K	0.01%	1425
2020 Q4	$449K	Hold	30,756	–	–	﹤0.01%	1538
2020 Q3	$437K	Hold	30,756	–	–	﹤0.01%	1440
2020 Q2	$452K	Buy	30,756 +4,406	+17%	+$44.8K	0.01%	1440
2020 Q1	$109K	Hold	26,350	–	–	﹤0.01%	2025
2019 Q4	$127K	Hold	26,350	–	–	﹤0.01%	2206
2019 Q3	$160K	Hold	26,350	–	–	﹤0.01%	2070
2019 Q2	$171K	Hold	26,350	–	–	﹤0.01%	2126
2019 Q1	$187K	Hold	26,350	–	–	﹤0.01%	2013
2018 Q4	$128K	Hold	26,350	–	–	﹤0.01%	2168
2018 Q3	$194K	Hold	26,350	–	–	﹤0.01%	2098
2018 Q2	$168K	Hold	26,350	–	–	﹤0.01%	2001
2018 Q1	$143K	Buy	+26,350	New	+$131K	﹤0.01%	2065

MetLife Investment Management's GNMK Position: Q2 2021 in Review

MetLife Investment Management sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 24,907 shares — an estimated $595K sold.

MetLife Investment Management first reported a position in GNMK in Q1 2018 and held it in 13 quarters. The position peaked at $595K in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.

MetLife Investment Management reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
MetLife Investment Management sold 24,907 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $595K.
MetLife Investment Management first reported a position in GenMark Diagnostics, Inc in Q1 2018 and held it in 13 quarters.
MetLife Investment Management's GenMark Diagnostics, Inc position peaked at $595K in Q1 2021.
0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.

Based on MetLife Investment Management's 13F filing for Q2 2021, filed 16 Aug 2021.